Novavax, Inc. (NASDAQ:NVAX) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Novavax, Inc. (NASDAQ:NVAX) have been assigned an average recommendation of “Hold” from the twelve research firms that are currently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $36.00.

A number of research analysts have weighed in on the stock. Zacks Investment Research raised shares of Novavax from a “hold” rating to a “buy” rating and set a $8.00 price objective for the company in a report on Thursday, May 16th. Chardan Capital reaffirmed a “neutral” rating and issued a $7.00 price objective on shares of Novavax in a report on Friday, May 10th. HC Wainwright lifted their price objective on shares of Novavax from $10.00 to $17.00 and gave the company a “buy” rating in a report on Wednesday, August 14th. Cantor Fitzgerald reaffirmed a “hold” rating on shares of Novavax in a report on Thursday, May 9th. Finally, ValuEngine raised shares of Novavax from a “sell” rating to a “hold” rating in a report on Thursday, August 1st.

NASDAQ NVAX opened at $6.55 on Friday. The company has a fifty day simple moving average of $4.99 and a two-hundred day simple moving average of $3.31. The stock has a market cap of $159.56 million, a P/E ratio of -0.65 and a beta of 2.21. Novavax has a 12-month low of $4.01 and a 12-month high of $51.60.

Novavax (NASDAQ:NVAX) last issued its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.61) by ($0.08). The company had revenue of $3.36 million for the quarter, compared to analysts’ expectations of $3.53 million. During the same period in the previous year, the business posted ($2.40) earnings per share. On average, sell-side analysts forecast that Novavax will post -5.6 earnings per share for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Edmond DE Rothschild Holding S.A. boosted its position in Novavax by 86.7% during the first quarter. Edmond DE Rothschild Holding S.A. now owns 1,537,130 shares of the biopharmaceutical company’s stock worth $847,000 after acquiring an additional 713,752 shares during the last quarter. Creative Planning boosted its holdings in Novavax by 161.7% in the 1st quarter. Creative Planning now owns 513,324 shares of the biopharmaceutical company’s stock valued at $283,000 after purchasing an additional 317,204 shares during the last quarter. SG Americas Securities LLC boosted its holdings in Novavax by 3,799.2% in the 1st quarter. SG Americas Securities LLC now owns 435,107 shares of the biopharmaceutical company’s stock valued at $240,000 after purchasing an additional 423,948 shares during the last quarter. DekaBank Deutsche Girozentrale boosted its holdings in Novavax by 21.8% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 123,100 shares of the biopharmaceutical company’s stock valued at $185,000 after purchasing an additional 22,000 shares during the last quarter. Finally, Ontario Teachers Pension Plan Board acquired a new position in Novavax in the 2nd quarter valued at about $510,000.

Novavax Company Profile

Novavax, Inc, together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant that is in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase II clinical trial for treating seasonal influenza in older adults.

Recommended Story: Stop Order

Analyst Recommendations for Novavax (NASDAQ:NVAX)

Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.